Semaglutide Side Effects: What the Trials Actually Report

For a focused discussion of bowel changes, what to record and when to get help, see GLP-1 constipation.

Semaglutide has the longest track record of any GLP-1 used for weight management, which means its side-effect profile is also the best-documented. This guide reports what the pivotal trials and a dedicated safety meta-analysis actually found — not what a forum thread claims.

For symptom-specific follow-up, see diarrhea and hydration, reflux and sulfur burps, and persistent fullness or suspected gastroparesis. These guides explain what symptoms can establish and when assessment is needed.

What are the most common semaglutide side effects?

In semaglutide's pivotal 68-week weight-management trial, gastrointestinal events — nausea, diarrhea, vomiting and constipation — were the most frequently reported adverse events, and they were more common than on placebo¹. A systematic review and meta-analysis focused specifically on semaglutide's efficacy and safety in obesity without diabetes reaches the same conclusion across the pooled trial evidence: GI effects dominate the side-effect profile, generally mild to moderate in severity and more frequent during dose escalation². This is the same pattern reported for tirzepatide — it is a class effect of GLP-1 receptor agonism, not a quirk of one molecule.

How many people stop semaglutide because of side effects?

In the pivotal trial, more participants on semaglutide discontinued treatment due to an adverse event than on placebo, with GI events cited as the leading reason¹. As with tirzepatide, that is a real, non-zero number — and also not the majority outcome, since most trial participants remained on treatment for the full study period. If your body's reaction hasn't eased after the first several weeks on a given dose, you are not the only person for whom that happened in the trial data.

The long-view safety data: SELECT

Because Wegovy has been studied specifically for cardiovascular outcomes, there is unusually strong long-view safety evidence: the SELECT trial followed over 17,000 adults with cardiovascular disease and overweight or obesity (without diabetes) on semaglutide for a median of about three years and found a reduction in major adverse cardiovascular events compared with placebo, with a safety profile consistent with semaglutide's established GI-effect pattern³. That is one of the longest and largest safety datasets behind any GLP-1, and it is specific to the FDA-approved brand product — not automatically transferable to a compounded version of the same molecule, which is why pharmacy verification matters regardless of which molecule you choose.

Our SELECT heart-outcomes guide explains the trial population and the difference between relative and absolute benefit.

What does the semaglutide label warn about?

Semaglutide's FDA labeling carries the same class-level warnings as tirzepatide's: a boxed warning about thyroid C-cell tumor risk seen in rodent studies (unconfirmed in humans, but screened for at intake), plus warnings for pancreatitis, gallbladder disease, and hypoglycemia risk when combined with insulin or a sulfonylurea. What the RCT meta-analyses and large real-world cohorts actually show behind those last two warnings — a confirmed gallbladder risk, and a pancreatitis picture more nuanced than the label alone suggests — is covered in full in GLP-1s, pancreatitis and gallbladder risk. A provider's clinical review — a scored factor in our methodology — is where this screening is actually supposed to happen, not a step to shop past for a lower price. A few other areas worth knowing the real evidence on: hair loss on a GLP-1 and the closely related facial and skin changes some patients notice, pregnancy, fertility and breastfeeding, where the guidance turns out to depend on details most people never hear, and emerging trial evidence on whether semaglutide affects alcohol cravings, a genuinely different question from whether it's safe to drink on it.

For a separate discussion of eye concerns, read semaglutide, vision changes and NAION. It distinguishes urgent symptoms, diabetic retinopathy and the European regulatory finding rather than treating them as one problem.

What this means before you buy

Expect GI symptoms during titration, expect them to ease as your dose stabilizes, and know that stopping because it doesn't ease is a documented outcome for a real minority, not evidence something unusual happened to you specifically. Follow the labeled titration schedule rather than a faster provider-set pace, and use a provider with real clinician oversight. For the molecule-vs-molecule tradeoff on both efficacy and price, see semaglutide vs tirzepatide value; if you're weighing whether to keep paying for treatment at all, see what happens when you stop a GLP-1. Mood changes are a separate, less-discussed concern worth its own read — see GLP-1s, depression, anxiety and mood changes for what the pharmacovigilance and FDA safety review actually show. Not medical advice — see our medical disclaimer and talk to a clinician about your own history.